Work

38P Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma

Year: 2024

Type: article

Abstract: Immune Checkpoint Inhibitors (ICIs) have substantially improved the prognosis of metastatic melanoma. However, not all patients benefit equally. To optimize patient selection for ICIs and minimize immune-related toxicity in those with a low likelihood of response, it is essential to identify predictive biomarkers. Our study assessed the association between certain patient characteristics and response to ICIs, progression-free survival (PFS), and overall survival (OS).

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100920

Authors: E.M. Bob, C.C. Burz

Institutions: Iuliu Hațieganu University of Medicine and Pharmacy, Institute of Oncology Prof. Dr. Ion Chiricuta

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170